S670
Clinical – Head & neck
ESTRO 2026
Conclusion: The study findings suggest that daily prophylactic IV fluid supplementation during chemoradiotherapy reduces weight loss and mitigates the severity of mucositis without increasing the risk. A notable proportion of control patients required unplanned IV hydration, supporting the potential role of this
intervention. References:
1..Mooney J. Effect of regularly scheduled artificial hydration on treatment outcomes in head and neck cancer patients undergoing radiotherapy. 2013 2. Fredman E, Kharouta M, Chen E, Gross A, Dorth J, Patel M, et al. Dehydration Reduction in Head and Neck Cancer (DRIHNC) Trial: Daily Oral Fluid and Electrolyte Maintenance to Prevent Acute Care Clinic and Emergency Department Visits for Patients
Receiving Radiation for Head and Neck and Esophageal Cancer. Adv Radiat Oncol. 2022;7(6):101026. Keywords: Concurrent chemoradiotherapy, Prophylactic fluids
Digital Poster 5003
Radiation therapy for synchronous oligometastatic Nasopharyngeal cancer in a low-middle-income country Najla Attia, Rim Abidi, Khadija Ben Zid, Cyrine Mokrani, Chiraz Nasr radiotherapy, Salah Azaiez's Institute, Tunis, Tunisia Purpose/Objective: Nasopharyngeal cancer, prevalent in Tunisia, is often diagnosed at an advanced stage. The therapeutic approach for metastatic forms has evolved with the concept of oligometastasis. Our study aims to evaluate the effectiveness of curative locoregional radiotherapy in these cases, with the objectives of estimating overall and progression-free survival and identifying prognostic factors Material/Methods: This was a retrospective study, including 50 patients treated with curative radiotherapy for oligometastatic nasopharyngeal cancer from January 1st, 2015, to December 31, 2021, at the Salah Azaiez Institute. Results: The mean age was 49.6 years, with a male predominance (68%). Initial symptoms were mainly rhinological (38%) and cervical lymphadenopathy (34%). Most patients presented with an advanced stage (T3-T4: 60%, N3: 52%). Metastases were most often osseous (46%), pulmonary (38%), or visceral (liver, extra-cervical lymph nodes: 18%). Thirty-six percent of patients had a single metastatic site, while 30% had more than two. All patients received
In the Intervention arm 39 and in the Control arm 41 patients were included for per protocol analysis (Figure 1, Table 1). In the Intervention arm, 11/39 (28.2%) completed 5 cycles of planned chemotherapy compared to 10/41 (24.4%) in the Control arm (p value = 0.698). The median number of chemotherapy cycles received by the Intervention arm was 4 while it was 3 for the Control arm. Twelve (29.3%) patients in the Control arm required unplanned intravenous fluid administration as an additional supportive measure. The need for NG tube insertion, unplanned admission, and unplanned interventions was similar in both arms. The incidence of grade 3 mucositis in both groups was similar, while the onset and duration of Grade 3 mucositis were delayed and shorter in the Intervention arm. Radiation breaks greater than 3 days were similar in both groups. Grade > 2 weight loss was significantly lower in the Intervention arm (7.7% vs 26.8%, p value = 0.024). All the patients in the Intervention arm adhered well to the intravenous fluid administration. None of the patients in the Intervention arm developed any complications related to intravenous fluid administration such as thrombophlebitis, extravasation or fluid overload. (Table 2)
Made with FlippingBook - Share PDF online